𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Updated cost-effectiveness projections for donepezil in the treatment of patients with mild-to-moderately severe Alzheimer's disease in the UK

✍ Scribed by Maclaine, Grant; Getsios, Denis; Blume, Steve; Ishak, Jack

Book ID
122670567
Publisher
Elsevier Science
Year
2009
Tongue
English
Weight
43 KB
Volume
5
Category
Article
ISSN
1552-5260

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Cost-effectiveness analysis of donepezil
Cost-effectiveness analysis of donepezil for mild to moderate Alzheimer's disease in Taiwan
✍ Jong-Ling Fuh; Shuu-Jiun Wang πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 117 KB πŸ‘ 2 views

## Abstract ## Background Donepezil is a drug used for treatment in patients with Alzheimer's disease (AD). Information regarding the cost‐effectiveness of this medication was previously rare in Asia. We used techniques of decision analysis and economic evaluation in conjunction with available loc

Tolerability of switching from donepezil
Tolerability of switching from donepezil to memantine treatment in patients with moderate to severe Alzheimer's disease
✍ Gunhild Waldemar; Maritta HyvΓ€rinen; Mette Krog Josiassen; Alex KΓΈrner; Heikki L πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 44 KB πŸ‘ 2 views

This study investigates the tolerability, safety and efficacy of abrupt or stepwise switching from donepezil to memantine treatment in patients with moderate-to-severe Alzheimer's disease (AD). Outpatients (Table 1), !50 years, with dementia of the Alzheimer's type (DSM-IV-TR), MMSE 18 and receiving